Kailera Therapeutics, Inc. (KLRA)Healthcare | Biotechnology | Waltham, United States | NasdaqGS
11.71 USD
+0.97
(9.032%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 9:53 a.m. EDT
Kailera Therapeutics presents a classic biotech dilemma: a massive analyst consensus target price of $42.40 clashes violently with the reality of negative earnings, negative forward P/E, and a stock trading near its 52-week lows. While the company boasts a fortress balance sheet with $916M in cash against minimal debt and a pristine current ratio of 11x, the market is pricing in significant execution risk, evidenced by the heavy short interest and the stock's failure to recover from its IPO highs. The recent price action shows a distinct downtrend, closing the last session near the $10 level after failing to breach the $13 resistance zone. With no dividend to provide income and a statistical forecast leaning slightly negative despite low confidence, the short-term outlook remains bearish as the stock digests the gap between its lofty analyst expectations and its deteriorating technical structure. Long-term, the business fundamentals are sound enough to warrant a neutral hold pending clinical milestones, but the current valuation implies the market expects a long road to profitability. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.108118 |
| AutoETS | 0.132238 |
| AutoARIMA | 0.132747 |
| MSTL | 0.134103 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 34% |
| H-stat | 18.06 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.068 |
| Excess Kurtosis | -0.47 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.913 |
| Market Cap | 1,518,127,488 |
| Forward P/E | -2.73 |
| Website | https://www.kailera.com |
As of Oct. 10, 2026, 9:53 a.m. EDT: Options activity is virtually dormant with negligible open interest and volume across both calls and puts. The lack of positioning suggests speculators are currently sidelined or waiting for clinical data clarity rather than betting on immediate directional moves.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.58692306 |
| Address1 | 180 Third Avenue |
| Address2 | 4th Floor |
| All Time High | 28.23 |
| All Time Low | 9.76 |
| Ask | 13.54 |
| Ask Size | 2 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 1,516,890 |
| Average Daily Volume3 Month | 933,990 |
| Average Volume | 933,990 |
| Average Volume10Days | 1,516,890 |
| Bid | 8.46 |
| Bid Size | 2 |
| Book Value | 8.629 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.71 |
| Current Ratio | 11.108 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 11.76 |
| Day Low | 10.5 |
| Debt To Equity | 0.913 |
| Display Name | Kailera Therapeutics |
| Dividend Yield | 0.0 |
| Earnings Timestamp | 1,793,822,400 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | -312,878,016 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -1.955 |
| Enterprise Value | 611,602,432 |
| Eps Current Year | -4.09671 |
| Eps Forward | -4.296 |
| Eps Trailing Twelve Months | -4.51 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 14.6584 |
| Fifty Day Average Change | -2.9483995 |
| Fifty Day Average Change Percent | -0.20114061 |
| Fifty Two Week Change Percent | -58.692307 |
| Fifty Two Week High | 28.23 |
| Fifty Two Week High Change | -16.52 |
| Fifty Two Week High Change Percent | -0.5851931 |
| Fifty Two Week Low | 9.76 |
| Fifty Two Week Low Change | 1.9499998 |
| Fifty Two Week Low Change Percent | 0.19979505 |
| Fifty Two Week Range | 9.76 - 28.23 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,776,432,600,000 |
| Float Shares | 58,478,373 |
| Forward Eps | -4.296 |
| Forward P E | -2.7257915 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 145 |
| Fullday Change | 1.0100002 |
| Fullday Change Percent | 9.4040985 |
| Fullday Price | 11.71 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.089090005 |
| Held Percent Institutions | 0.90391 |
| Implied Shares Outstanding | 129,643,676 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-04-17 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts. |
| Long Name | Kailera Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 1,518,127,488 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_1899116257 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -292,196,992 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,702,221,465 |
| Number Of Analyst Opinions | 5 |
| Open | 10.55 |
| Operating Cashflow | -221,615,008 |
| Operating Margins | 0.0 |
| Phone | 781 317 0290 |
| Previous Close | 10.74 |
| Price Eps Current Year | -2.858391 |
| Price Hint | 2 |
| Price To Book | 1.3570518 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.032 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.16667 |
| Region | US |
| Regular Market Change | 0.97 |
| Regular Market Change Percent | 9.03166 |
| Regular Market Day High | 11.76 |
| Regular Market Day Low | 10.5 |
| Regular Market Day Range | 10.5 - 11.76 |
| Regular Market Open | 10.55 |
| Regular Market Previous Close | 10.74 |
| Regular Market Price | 11.71 |
| Regular Market Time | 1,792,094,401 |
| Regular Market Volume | 1,174,315 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 129,643,676 |
| Shares Percent Shares Out | 0.067 |
| Shares Short | 8,683,381 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 5,660,876 |
| Short Name | Kailera Therapeutics, Inc. |
| Short Percent Of Float | 0.067 |
| Short Ratio | 7.26 |
| Source Interval | 15 |
| State | MA |
| Symbol | KLRA |
| Target High Price | 57.0 |
| Target Low Price | 30.0 |
| Target Mean Price | 42.4 |
| Target Median Price | 41.0 |
| Total Cash | 916,740,992 |
| Total Cash Per Share | 7.071 |
| Total Debt | 10,216,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -4.51 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 18.48568 |
| Two Hundred Day Average Change | -6.7756796 |
| Two Hundred Day Average Change Percent | -0.36653668 |
| Type Disp | Equity |
| Volume | 1,174,315 |
| Website | https://www.kailera.com |
| Zip | 2,451 |